Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma.
Am J Clin Oncol
; 25(5): 468-73, 2002 Oct.
Article
en En
| MEDLINE
| ID: mdl-12393986
ABSTRACT
This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Sarcoma
/
Epirrubicina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Antibióticos Antineoplásicos
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Clin Oncol
Año:
2002
Tipo del documento:
Article
País de afiliación:
Italia